Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms.
New combination therapies and decision tools help doctors choose between gentler and intensive AML treatments based on individual patient genetics and disease features.
This authoritative 2026 review by Gangat (Mayo Clinic) and Ravandi (MD Anderson) synthesizes updated AML treatment decision algorithms for fit patients incorporating venetoclax, targeted inhibitors of FLT3 (midostaurin/quizartinib), IDH1/2, and menin, alongside intensive regimens. Key algorithm updates include consideration of VEN-HMA-FLT3i triplets as intensive chemotherapy alternatives, MRD-guided allogeneic transplant decisions, and the emerging data suggesting VEN-HMA may approach intensive chemotherapy in selected patients proceeding to transplant.
What the study was
- Study design
- expert_review
- Population
- Newly diagnosed AML patients fit for intensive therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood Cancer J
Why it surfaced
Essential, timely reference for the AML watchlist; integrates the latest clinical trial data from Blood Cancer J, a high-impact focused journal; directly actionable treatment decision support covering FLT3, IDH, menin, and venetoclax combination approaches.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.